Type VI Secretion System in Klebsiella Pneumoniae

Study Overview
=================
Brief Summary
-----------------
Klebsiella pneumoniae (K. pneumoniae) is an important opportunistic pathogen contributing to nosocomial and antimicrobial-resistant infections. The increasing prevalence of infections caused by multidrug-resistant K. pneumoniae has emerged as a major clinical and public health threat, while the serous organ and life-threatening infections caused by highly virulent K. pneumoniae have also emerged( Russo and Marr, 2019; Wyres et al., 2020).

Detailed Description
-----------------
Both drug-resistant and highly virulent K. pneumoniae have brought major challenges to clinical treatment and stimulated interest in studying K. pneumoniae. However, knowledge of the genomics, ecology, and pathogenicity of K. pneumoniae is relatively limited. Recently, the type VI secretion system (T6SS) was identified as a virulence factor in K. pneumoniae (Martin and Bachman, 2018). Furthermore, K. pneumoniae was found to exploit the T6SS nano-weapon to destroy bacterial competitors and fungi (Storey et al., 2020). The bacterial Type VI Secretion System (T6SS) is a membrane-attached contractile phage tail that is physically and Mechanistically similar to a membrane-linked intracellular contractile phage tail. T6SS spike and tube elements, as well as anti-bacterial and anti-eukaryotic effectors, are propelled out of predatory T6SS positive cells and into target cells by a fast conformational shift in the structural framework of a sheath protein complex, according to recent research (Kudryashev et al., 2015). However, the limited studies and lack of information on the T6SS in K. pneumoniae necessitate further exploration to clarify the physiological metabolism and pathogenic information of this clinically important bacterial species.

Official Title
-----------------
Type VI Secretion System in Klebsiella Pneumoniae Relation to Antibiotic Resistance and Biofilm Formation

Conditions
-----------------
Detection of Type VI Secretion System in K.Pneumoniae, Detection of Relation to Ab Resistance, Biofilm

Intervention / Treatment
-----------------
* Diagnostic Test: Routine bacteriological cultures
* Diagnostic Test: Identification of the organism and antibiotic sensitivity will be done by VITEK II
* Diagnostic Test: Detection of biofilm formation
* Diagnostic Test: Molecular detection by PCR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients suffering from infections that can be caused by Klebsiella Pneumoniae. Exclusion Criteria: Samples diagnosed to have organisms other than Klebsiella Pneumoniae

Ages Eligible for Study
-----------------
Minimum Age: 12 Weeks
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Routine bacteriological cultures|culture of different samples on different culture media as nutrient agar, blood agar, MacConkey agar, EMB agar, TSI|
|Diagnostic Test: Identification of the organism and antibiotic sensitivity will be done by VITEK II|Automated identification of the organism and antibiotic sensitivity will be done by VITEK II|
|Diagnostic Test: Detection of biofilm formation|Detection of Biofilm formation to the collected organism by tissue culture plate method.|
|Diagnostic Test: Molecular detection by PCR|Molecular detection of Type VI Secretion System genes, capsular serotyping( k1, k2), and FimH genes by PCR.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Isolation and identification of Klebsiella Pneumoniae isolated from different samples and determination of their antibiotics profile |  | 1 september 2022 to 1 November 2022 | 
| Detection of Type VI Secretion System In Klebsiella Pneumoniae and its relation to Antibiotic Resistance and biofilm formation |  | 2 November 2022 to February 2023 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type IV, secretion system, Klebsiella Pneumoniae